Early tumor shrinkage predicts targeted therapy efficacy

Early tumor shrinkage in patients with metastatic renal cell carcinoma (mRCC) following vascular endothelial growth factor (VEGF)-targeted therapy may herald good long-term survival, research shows.12/12/2013
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news